INDEMNITY AGREEMENT

THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of [●], by and between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and [●] (“Indemnitee”).

RECITALS

WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of such corporations;

…

May 13, 2026

***BY EMAIL ***

Christopher Downs

RE:   Separation from CNS Pharmaceuticals, Inc.

** **

Dear Christopher,

As you are aware, CNS Pharmaceuticals, Inc. (the “Company”) has made the difficult decision to terminate your employment, effective as of May 13, 2026 (the “Separation Date”). You will receive your final paycheck within the time required by law. Please submit a request for reimbursement and supporting documentation within seven (7) days of the Separation Date for all unpaid business expenses incurred prior to the Separation Date. The Company shall reimburse you for such expenses consistent with Company policy.

In consideration for your execution of this Agreement (this “Agreement”) and the mutual exchange of other promises, the receipt and sufficiency of which are hereby acknowledged, the Company is offering to provide you with certain severance benefits, described below.

…

Xilio Therapeutics, Inc.

THIRD AMENDED AND RESTATED

2022 INDUCEMENT STOCK INCENTIVE PLAN

1.

Purpose

The purpose of this Second Amended and Restated 2022 Inducement Stock Incentive Plan (the “Plan”) of Xilio Therapeutics, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company with an inducement material for such persons to enter into employment with the Company and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of the Company’s stockholders. Except where the context otherwise requires, the term “Company” shall include any of the Company’s present or future parent or subsidiary corporations as defined in Sections 424(e) or (f) of the Internal Revenue Code of 1986, as amended, and any regulations thereunder (the “Code”) and any other business venture (including, without limit

…

ARBUTUS BIOPHARMA CORPORATION 2026 OMNIBUS SHARE AND INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT COVER SHEET Arbutus Biopharma Corporation, a company incorporated under the laws of the Province of British Columbia (the “Company”), hereby grants an option (the “Option”) to purchase the Company’s common shares, without par value (the “Common Shares”), to the Grantee named below, subject to the vesting and other conditions set forth below. Additional terms and conditions of the Option are set forth in this cover sheet and in the attached Incentive Stock Option Agreement (together, the “Agreement”) and in the Arbutus Biopharma Corporation 2026 Omnibus Share and Incentive Plan (as it has been or may be amended and/or restated from time to time, the “Plan”). Name of Grantee: [●] Grant Date: [●] Number of Common Shares Covered by the Option: [●] Option Price per Common Share: [●] Vesting Commencement Date: [●] Vesting Schedule: The Option shall vest as follows: one third to vest on [INSERT DATE]; one third to vest on [INSERT DATE] and one third to vest on [INSERT DATE], while th

…

ARBUTUS BIOPHARMA CORPORATION 2026 OMNIBUS SHARE AND INCENTIVE PLAN RESTRICTED SHARE UNIT AGREEMENT (U.S.) COVER SHEET Arbutus Biopharma Corporation, a company incorporated under the laws of the Province of British Columbia (the “Company”), hereby grants restricted share units (the “RSUs”) relating to the Company’s common shares, without par value (the “Common Shares”), to the Grantee named below, subject to the vesting and other conditions set forth below. Additional terms and conditions of the RSUs are set forth in this cover sheet and in the attached Restricted Share Unit Agreement (together, the “Agreement”) and in the Arbutus Biopharma Corporation 2026 Omnibus Share and Incentive Plan (as it has been or may be amended and/or restated from time to time, the “Plan”). Name of Grantee: [●] Grant Date: [●] Number of Common Shares Covered by the RSUs: [●] Vesting Commencement Date: [●] Vesting Schedule: [●] By your electronic acknowledgement of this Agreement, you agree to all of the terms and conditions described in the Agreement and in the Plan (a copy of which has been made av

…

August 10, 2026

3i, LP
2 Wooster Street, 2nd Floor
New York, New York 10013
Attn: Maier J. Tarlow

Re: Conversion Price Voluntary Adjustment Notice

Dear Sirs:

Reference is made to (a) that certain Securities Purchase Agreement dated as of July 29, 2025 (the “Purchase Agreement”) between Capstone Holding Corp. (the “Company”) and 3i, LP (the “Investor”), (b) the senior secured convertible notes of the Company, each with a 8.34% original issue discount, issued to the Investor on July 29, 2025 (as amended, including pursuant to that certain First Amendment thereto) and October 22, 2025 (each, a “Note” and together, the “Notes”), and (c) the other transaction documents, as modified from time to time, referred to collectively, as the “Transaction Documents”. Capitalized terms used but not defined herein shall have the meanings given to them in the Purchase Agreement, or if not defined therein, in the applicable Note, or if not defined therein, in the applicable Transaction Document, in each case as of the date hereof.

…

CAPSTONE HOLDING CORP.

**2025 Stock Incentive Plan **

Master Restricted Stock Agreement

Capstone Holding Corp. (the “Company”) and the Recipient named below each hereby into this Master Restricted Stock Agreement on the execution date specified in the table below (including the Terms and Conditions attached hereto, the “Agreement”). The Company grants to the Recipient the shares of Restricted Stock specified herein on the dates specified herein pursuant to the Capstone Holding Corp. 2025 Stock Incentive Plan, as amended and in effect from time to time (the “Plan”).

…

CAPSTONE HOLDING CORP.

**2025 Stock Incentive Plan **

Master Restricted Stock Agreement

Capstone Holding Corp. (the “Company”) and the Recipient named below each hereby into this Master Restricted Stock Agreement on the execution date specified in the table below (including the Terms and Conditions attached hereto, the “Agreement”). The Company grants to the Recipient the shares of Restricted Stock specified herein on the dates specified herein pursuant to the Capstone Holding Corp. 2025 Stock Incentive Plan, as amended and in effect from time to time (the “Plan”).

…

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Center for Technology Licensing

1155 York Avenue New York, NY 10065 P: 646.962.7045

innovation.weill.cornell.edu

Weill Cornell Medicine Enterprise Innovation

April 28, 2026

[***]

RE: THIRD AMENDMENT

to the THIRD LICENSE AGREEMENT by and between Lexeo Therapeutics, Inc. (hereinafter “Licensee”) and Cornell University (“Cornell”) (each a “Party”) effective April 21, 2024, amended a first time effective May 24, 2024, and amended a second time effective December 22, 2025 (the “Third License Agreement”) (CTL Contract No. [***])

WHEREAS, Section 1 of the Second Amendment to this Agreement (effective December 22, 2025) refers to "Paragraph 3.1" being deleted and replaced; the Parties acknowledge that this reference was a scrivener's error, and that the Parties intended to delete and replace only Paragraph 3.1(a);

…

​

SECOND AMENDMENT TO

NOTE PURCHASE AGREEMENT

​

This SECOND AMENDMENT TO NOTE PURCHASE AGREEMENT, dated as of January 12, 2026 (“Amendment”), is made by and among Milestone Pharmaceuticals Inc., a corporation existing under the Business Corporations Act (Québec) (the “Company”), the Purchasers (defined below), RTW Investments, LP, as agent for the Purchasers (in such capacity, the “Principal Purchaser”) and acknowledged and agreed by Acquiom Agency Services LLC, as collateral agent for the Purchasers (in such capacity, the “Collateral Agent”). Capitalized terms used herein, but not otherwise defined herein shall have the respective meanings set forth in the Note Purchase Agreement (defined below).

W I T N E S S E T H:

​

…

​

THIRD AMENDMENT TO

NOTE PURCHASE AGREEMENT

This THIRD AMENDMENT TO NOTE PURCHASE AGREEMENT, dated as of June 29, 2026 (this “Amendment”), is made by and among Milestone Pharmaceuticals Inc., a corporation existing under the Business Corporations Act (Québec) (the “Company”), the Purchasers (defined below), RTW Investments, LP, as agent for the Purchasers (in such capacity, the “Principal Purchaser”). Capitalized terms used herein, but not otherwise defined herein, shall have the respective meanings set forth in the Note Purchase Agreement (defined below).

WITNESSETH:

…

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]”.

CREDIT AGREEMENT

BETWEEN

ENOVUM DATA CENTERS CORP.

as Borrower

** **

AND

ENOVUM MTL I GP INC., EDC MTL I LIMITED PARTNERSHIP, ENOVUM MTL II GP INC., EDC MTL II LIMITED PARTNERSHIP, ENOVUM SAINT-JEROME GP INC., EDC SAINT-JÉRÔME LIMITED PARTNERSHIP and 1504950 B.C. UNLIMITED LIABILITY COMPANY

as Guarantors

** **

AND

THE FINANCIAL INSTITUTIONS from time to time party to this Agreement and designated as Lenders on the signature pages hereto

as Lenders

** **

AND

ROYAL BANK OF CANADA

as Administrative Agent

** **

AND

ROYAL BANK OF CANADA

as Sole Lead Arranger and Sole Bookrunner

** **

MADE AS OF

** **

JULY 6, 2026

** **

TABLE OF CONTENTS

…